Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury

NCT02733328 is registered in ClinicalTrials.gov with The Royal Wolverhampton Hospitals NHS Trust as lead sponsor.

NCT NCT02733328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02733328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury
Lead sponsor
The Royal Wolverhampton Hospitals NHS Trust
Phase
Observational
Overall status
Completed
Start date
May 31, 2016
Completion date
September 7, 2020
Enrollment
405 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury (aki), chronic kidney disease (ckd), end stage renal disease (esrd), estimated glomerular filtration rate (egfr), neutrophil gelatinase-associated lipocalin (ngal), serum creatinine (scr), urine albumin (ualb), urine creatinine (ucr)